Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | F9 | P00740 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 6/20 | 0.39 |
| ▸ | MAOB | P27338 | 6/20 | 0.39 |
| ▸ | CTSV | O60911 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | SENP5 | Q96HI0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1615137 | 0.85 | GPR84 (0.41) | NPC1MAPTRAB9ACYP1A2CYP3A4 | |
| SCHEMBL4548605 | 0.85 | MAPT (0.34) | NPC1MAPTRAB9ACYP1A2CYP3A4 | |
| SCHEMBL2127382 | 0.84 | PTPN1 (0.49) | NPC1MAPTRAB9ACYP1A2CYP3A4 | |
| SCHEMBL10058703 | 0.84 | MAPT (0.41) | NPC1MAPTRAB9ACYP1A2CYP3A4 | |
| SCHEMBL1614172 | 0.82 | MAPT (0.43) | NPC1MAPTRAB9ACYP1A2CYP3A4 | |
| SCHEMBL13113515 | 0.81 | MAPT (0.42) | NPC1MAPTRAB9ACYP1A2CYP3A4 | |
| SCHEMBL25556876 | 0.80 | MAPT (0.58) | NPC1MAPTRAB9ACYP1A2CYP3A4 | |
| SCHEMBL31120499 | 0.79 | ALDH1A1 (0.40) | NPC1MAPTRAB9ACYP1A2CYP3A4 | |
| SCHEMBL2125461 | 0.79 | CYP1A2 (0.43) | NPC1MAPTRAB9ACYP1A2CYP3A4 | |
| SCHEMBL28669651 | 0.78 | F9 (0.49) | NPC1MAPTRAB9ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1485377-B9 | PYRANONES USEFUL AS ATM INHIBITORS | KUDOS PHARM LTD (GB) | 2010-10-06 | — | — | EP | disclosed |
| EP-2174939-A1 | Pyranones useful as ATM inhibitors | Kudos Pharmaceuticals Limited (GB) | 2010-04-14 | — | — | EP | disclosed |
| EP-1485377-B1 | PYRANONES USEFUL AS ATM INHIBITORS | KUDOS PHARM LTD (GB) | 2009-12-09 | — | — | EP | disclosed |
| CN-100358891-C | Pyranones useful as ATM inhibitors | KUDOS PHARM LTD (GB) | 2008-01-02 | — | — | CN | disclosed |
| US-7049313-B2 | ATM inhibitors | KUDOS PHARMACEUTICALS LTD. (GB) | 2006-05-23 | — | — | US | disclosed |
| CN-1639154-A | Pyranones useful as ATM inhibitors | KUDOS PHARM LTD (GB) | 2005-07-13 | — | — | CN | disclosed |
| EP-1485377-A1 | PYRANONES USEFUL AS ATM INHIBITORS | Kudos Pharmaceuticals Limited (GB) | 2004-12-15 | — | — | EP | disclosed |
| US-20040002492-A1 | Induce immunology response; anticancer agents | KUDOS PHARMACEUTICALS LTD (GB) | 2004-01-01 | — | — | US | disclosed |
| WO-2003070726-A1 | PYRANONES USEFUL AS ATM INHIBITORS | KUDOS PHARMACEUTICALS LTD (GB) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002492-A1 | Induce immunology response; anticancer agents | MYD88, IFNG, HCCS | NPC1 3751/4885MAPT 4832/4885RAB9A 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.